Cizzle Biotechnology Holdings
CIZ · Main Market · Health Care · mcap £6.3m · 1.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Results | Half-year Results
(“Cizzle", “Cizzle Biotechnology”, the “Company” or the “Group”) |
−8.8% |
| 03 Aug 26 | Laboratory Expansion to Accelerate Sales in USA
Further Laboratory Expansion to Accelerate Sales in USA |
+2.7% | |
| 22 Jul 26 | Update on Sales in USA
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to note that the Company's North American licensing partner Cizzle Bio Inc ("BIO"), has today announced the availability of the C |
+9.1% | |
| 15 Jul 26 | Half Year Operational Update
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce the following operational update and highlights for the six months ended 30 June 2026 ("H1 2026"). |
−7.0% | |
| 30 Jun 26 | Change of Corporate Broker
Cizzle Biotechnology is pleased to announce the appointment of Zeus Capital Limited as the Company's sole Corporate Broker with immediate effect. |
+2.0% | |
| 16 Jun 26 | Routine | Result of AGM | |
| 16 Jun 26 | CIZ1B Test Approved For Clinical Use in USA
CIZ1B Biomarker Test Approved For Clinical Use in USA |
+11.1% | |
| 12 Jun 26 | Patent Granted in USA
Cizzle Biotechnology, the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that a patent application covering the Company's core methods to measure the CIZ1B lung cancer biomarker has |
+7.3% | |
| 21 May 26 | Routine | Notice of AGM | |
| 07 May 26 | Issue of Options, Salary Waivers, Incentive Plan
Issue of Options, Salary Waivers and New Management Incentive Plan |
+11.1% | |
| 06 May 26 | Conversion of Convertible Loan Notes
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that the Company has received a notice to convert £400,000 of convertible loan notes ("CLNs") held by Frazer Lang (registered in t |
−3.1% | |
| 30 Apr 26 | Results | Final Results
Final results for the year ended 31 December 2025 |
−3.6% |
| 02 Apr 26 | £250,000 Funding Facility
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that it has entered into a new facility (the "Facility") to provide the Company with up to £250,000 through the potential issue of |
+0.0% | |
| 23 Feb 26 | Progress on Launch of Biomarker Test in USA
Progress on Commercial Launch of Biomarker Test in USA |
+11.5% | |
| 04 Feb 26 | Patent Granted in Canada
Cizzle Biotechnology, the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have |
+10.7% | |
| 05 Nov 25 | £250,000 Convertible Loan Note Issue
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce that it has raised up to £250,000 through the issue of further unsecured convertible loan notes ("Additional Notes") |
+6.1% | |
| 05 Nov 25 | LOI with leading UK Clinical Diagnostic Group
Letter of Intent signed with leading UK Clinical Diagnostic Group Providing Laboratory Services to the NHS |
+6.1% | |
| 27 Oct 25 | Routine | Change of Registered Office |
Company filings. Not investment advice.